Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
Identifieur interne : 001004 ( Main/Curation ); précédent : 001003; suivant : 001005Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
Auteurs : Michael Putman [États-Unis] ; Yu Pei Eugenia Chock [États-Unis] ; Herman Tam [Canada] ; Alfred H J. Kim [États-Unis] ; Sebastian E. Sattui [États-Unis] ; Francis Berenbaum [France] ; Maria I. Danila ; Peter Korsten [Allemagne] ; Catalina Sanchez-Alvarez [États-Unis] ; Jeffrey A. Sparks [États-Unis] ; Laura C. Coates [Royaume-Uni] ; Candace Palmerlee [États-Unis] ; Andrea Peirce [États-Unis] ; Arundathi Jayatilleke [États-Unis] ; Sindhu R. Johnson [Canada] ; Adam Kilian [États-Unis] ; Jean Liew [États-Unis] ; Larry J. Prokop [États-Unis] ; M Hassan Murad [États-Unis] ; Rebecca Grainger [Nouvelle-Zélande] ; Zachary S. Wallace [États-Unis] ; Alí Duarte-García [États-Unis]Source :
- Arthritis & rheumatology (Hoboken, N.J.) [ 2326-5205 ] ; 2021.
Descripteurs français
- KwdFr :
- Antagoniste du récepteur à l'interleukine-1 (usage thérapeutique), Anticorps monoclonaux (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (usage thérapeutique), Azétidines (usage thérapeutique), Biais (épidémiologie) (MeSH), Chloroquine (usage thérapeutique), Facteurs immunologiques (usage thérapeutique), Glucocorticoïdes (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Immunoglobulines par voie veineuse (usage thérapeutique), Inhibiteurs des Janus kinases (usage thérapeutique), Modèles des risques proportionnels (MeSH), Purines (usage thérapeutique), Pyrazoles (usage thérapeutique), Sulfonamides (usage thérapeutique), Évolution de la maladie (MeSH).
- MESH :
- usage thérapeutique : Antagoniste du récepteur à l'interleukine-1, Anticorps monoclonaux, Anticorps monoclonaux humanisés, Antirhumatismaux, Azétidines, Chloroquine, Facteurs immunologiques, Glucocorticoïdes, Hydroxychloroquine, Immunoglobulines par voie veineuse, Inhibiteurs des Janus kinases, Purines, Pyrazoles, Sulfonamides.
- Biais (épidémiologie), Humains, Modèles des risques proportionnels, Évolution de la maladie.
English descriptors
- KwdEn :
- Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (therapeutic use), Azetidines (therapeutic use), Bias (MeSH), COVID-19 (drug therapy), COVID-19 (mortality), COVID-19 (physiopathology), Chloroquine (therapeutic use), Disease Progression (MeSH), Glucocorticoids (therapeutic use), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunoglobulins, Intravenous (therapeutic use), Immunologic Factors (therapeutic use), Interleukin 1 Receptor Antagonist Protein (therapeutic use), Janus Kinase Inhibitors (therapeutic use), Proportional Hazards Models (MeSH), Purines (therapeutic use), Pyrazoles (therapeutic use), SARS-CoV-2 (MeSH), Sulfonamides (therapeutic use).
- MESH :
- chemical , therapeutic use : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Azetidines, Chloroquine, Glucocorticoids, Hydroxychloroquine, Immunoglobulins, Intravenous, Immunologic Factors, Interleukin 1 Receptor Antagonist Protein, Janus Kinase Inhibitors, Purines, Pyrazoles, Sulfonamides.
- drug therapy : COVID-19.
- mortality : COVID-19.
- physiopathology : COVID-19.
- Bias, Disease Progression, Humans, Proportional Hazards Models, SARS-CoV-2.
Abstract
OBJECTIVE
Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID-19) and its complications. We conducted a systematic review and meta-analysis to describe the current evidence.
METHODS
A search of published and preprint databases in all languages was performed. Included studies described ≥1 relevant clinical outcome for ≥5 patients who were infected with severe acute respiratory syndrome coronavirus 2 and were treated with antirheumatic disease therapy between January 1, 2019 and May 29, 2020. Pairs of reviewers screened articles, extracted data, and assessed risk of bias. A meta-analysis of effect sizes using random-effects models was performed when possible.
RESULTS
The search identified 3,935 articles, of which 45 were included (4 randomized controlled trials, 29 cohort studies, and 12 case series). All studies evaluated hospitalized patients, and 29 of the 45 studies had been published in a peer-reviewed journal. In a meta-analysis of 3 cohort studies with a low risk of bias, hydroxychloroquine use was not significantly associated with mortality (pooled hazard ratio [HR] 1.41 [95% confidence interval (95% CI) 0.83, 2.42]). In a meta-analysis of 2 cohort studies with some concerns/higher risk of bias, anakinra use was associated with lower mortality (pooled HR 0.25 [95% CI 0.12, 0.52]). Evidence was inconclusive with regard to other antirheumatic disease therapies, and the majority of other studies had a high risk of bias.
CONCLUSION
In this systematic review and meta-analysis, hydroxychloroquine use was not associated with benefit or harm regarding COVID-19 mortality. The evidence supporting the effect of other antirheumatic disease therapies in COVID-19 is currently inconclusive.
DOI: 10.1002/art.41469
PubMed: 32741139
PubMed Central: PMC7435536
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001004
Links to Exploration step
pubmed:32741139Curation
No country items
Maria I. Danila<affiliation><nlm:affiliation>University of Alabama at Birmingham.</nlm:affiliation><wicri:noCountry code="no comma">University of Alabama at Birmingham.</wicri:noCountry><wicri:noCountry code="no comma">University of Alabama at Birmingham.</wicri:noCountry></affiliation><affiliation><nlm:affiliation>University of Alabama at Birmingham.</nlm:affiliation><wicri:noCountry code="no comma">University of Alabama at Birmingham.</wicri:noCountry><wicri:noCountry code="no comma">University of Alabama at Birmingham.</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.</title><author><name sortKey="Putman, Michael" sort="Putman, Michael" uniqKey="Putman M" first="Michael" last="Putman">Michael Putman</name><affiliation wicri:level="1"><nlm:affiliation>Northwestern Medicine, Chicago, Illinois, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Northwestern Medicine, Chicago, Illinois</wicri:regionArea></affiliation></author><author><name sortKey="Chock, Yu Pei Eugenia" sort="Chock, Yu Pei Eugenia" uniqKey="Chock Y" first="Yu Pei Eugenia" last="Chock">Yu Pei Eugenia Chock</name><affiliation wicri:level="1"><nlm:affiliation>Yale School of Medicine, New Haven, Connecticut, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Yale School of Medicine, New Haven, Connecticut</wicri:regionArea></affiliation></author><author><name sortKey="Tam, Herman" sort="Tam, Herman" uniqKey="Tam H" first="Herman" last="Tam">Herman Tam</name><affiliation wicri:level="1"><nlm:affiliation>The Hospital for Sick Children, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Hospital for Sick Children, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Alfred H J" sort="Kim, Alfred H J" uniqKey="Kim A" first="Alfred H J" last="Kim">Alfred H J. Kim</name><affiliation wicri:level="1"><nlm:affiliation>Washington University School of Medicine, Saint Louis, Missouri, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea></affiliation></author><author><name sortKey="Sattui, Sebastian E" sort="Sattui, Sebastian E" uniqKey="Sattui S" first="Sebastian E" last="Sattui">Sebastian E. Sattui</name><affiliation wicri:level="1"><nlm:affiliation>Hospital for Special Surgery, New York, New York, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hospital for Special Surgery, New York, New York</wicri:regionArea></affiliation></author><author><name sortKey="Berenbaum, Francis" sort="Berenbaum, Francis" uniqKey="Berenbaum F" first="Francis" last="Berenbaum">Francis Berenbaum</name><affiliation wicri:level="1"><nlm:affiliation>Sorbonne Université, INSERM CRSA, AP-HP Hôpital Saint Antoine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sorbonne Université, INSERM CRSA, AP-HP Hôpital Saint Antoine, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Danila, Maria I" sort="Danila, Maria I" uniqKey="Danila M" first="Maria I" last="Danila">Maria I. Danila</name><affiliation><nlm:affiliation>University of Alabama at Birmingham.</nlm:affiliation><wicri:noCountry code="no comma">University of Alabama at Birmingham.</wicri:noCountry><wicri:noCountry code="no comma">University of Alabama at Birmingham.</wicri:noCountry></affiliation></author><author><name sortKey="Korsten, Peter" sort="Korsten, Peter" uniqKey="Korsten P" first="Peter" last="Korsten">Peter Korsten</name><affiliation wicri:level="1"><nlm:affiliation>University Medical Center Göttingen, Göttingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Medical Center Göttingen, Göttingen</wicri:regionArea></affiliation></author><author><name sortKey="Sanchez Alvarez, Catalina" sort="Sanchez Alvarez, Catalina" uniqKey="Sanchez Alvarez C" first="Catalina" last="Sanchez-Alvarez">Catalina Sanchez-Alvarez</name><affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic, Rochester, Minnesota, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Rochester, Minnesota</wicri:regionArea></affiliation></author><author><name sortKey="Sparks, Jeffrey A" sort="Sparks, Jeffrey A" uniqKey="Sparks J" first="Jeffrey A" last="Sparks">Jeffrey A. Sparks</name><affiliation wicri:level="1"><nlm:affiliation>Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts</wicri:regionArea></affiliation></author><author><name sortKey="Coates, Laura C" sort="Coates, Laura C" uniqKey="Coates L" first="Laura C" last="Coates">Laura C. Coates</name><affiliation wicri:level="1"><nlm:affiliation>University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Oxford, Oxford</wicri:regionArea></affiliation></author><author><name sortKey="Palmerlee, Candace" sort="Palmerlee, Candace" uniqKey="Palmerlee C" first="Candace" last="Palmerlee">Candace Palmerlee</name><affiliation wicri:level="1"><nlm:affiliation>••, Berkeley, California, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>••, Berkeley, California</wicri:regionArea></affiliation></author><author><name sortKey="Peirce, Andrea" sort="Peirce, Andrea" uniqKey="Peirce A" first="Andrea" last="Peirce">Andrea Peirce</name><affiliation wicri:level="1"><nlm:affiliation>••, New York, New York, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>••, New York, New York</wicri:regionArea></affiliation></author><author><name sortKey="Jayatilleke, Arundathi" sort="Jayatilleke, Arundathi" uniqKey="Jayatilleke A" first="Arundathi" last="Jayatilleke">Arundathi Jayatilleke</name><affiliation wicri:level="1"><nlm:affiliation>Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania</wicri:regionArea></affiliation></author><author><name sortKey="Johnson, Sindhu R" sort="Johnson, Sindhu R" uniqKey="Johnson S" first="Sindhu R" last="Johnson">Sindhu R. Johnson</name><affiliation wicri:level="1"><nlm:affiliation>Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Kilian, Adam" sort="Kilian, Adam" uniqKey="Kilian A" first="Adam" last="Kilian">Adam Kilian</name><affiliation wicri:level="1"><nlm:affiliation>George Washington University School of Medicine and Health Sciences, Washington, DC, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>George Washington University School of Medicine and Health Sciences, Washington, DC</wicri:regionArea></affiliation></author><author><name sortKey="Liew, Jean" sort="Liew, Jean" uniqKey="Liew J" first="Jean" last="Liew">Jean Liew</name><affiliation wicri:level="4"><nlm:affiliation>University of Washington, Seattle.</nlm:affiliation><orgName type="university">Université de Washington</orgName><country>États-Unis</country><placeName><settlement type="city">Seattle</settlement><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Prokop, Larry J" sort="Prokop, Larry J" uniqKey="Prokop L" first="Larry J" last="Prokop">Larry J. Prokop</name><affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic, Rochester, Minnesota, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Rochester, Minnesota</wicri:regionArea></affiliation></author><author><name sortKey="Murad, M Hassan" sort="Murad, M Hassan" uniqKey="Murad M" first="M Hassan" last="Murad">M Hassan Murad</name><affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic, Rochester, Minnesota, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Rochester, Minnesota</wicri:regionArea></affiliation></author><author><name sortKey="Grainger, Rebecca" sort="Grainger, Rebecca" uniqKey="Grainger R" first="Rebecca" last="Grainger">Rebecca Grainger</name><affiliation wicri:level="1"><nlm:affiliation>University of Otago, Wellington, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>University of Otago, Wellington</wicri:regionArea></affiliation></author><author><name sortKey="Wallace, Zachary S" sort="Wallace, Zachary S" uniqKey="Wallace Z" first="Zachary S" last="Wallace">Zachary S. Wallace</name><affiliation wicri:level="1"><nlm:affiliation>Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts</wicri:regionArea></affiliation></author><author><name sortKey="Duarte Garcia, Ali" sort="Duarte Garcia, Ali" uniqKey="Duarte Garcia A" first="Alí" last="Duarte-García">Alí Duarte-García</name><affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic, Rochester, Minnesota, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Rochester, Minnesota</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:32741139</idno><idno type="pmid">32741139</idno><idno type="doi">10.1002/art.41469</idno><idno type="pmc">PMC7435536</idno><idno type="wicri:Area/Main/Corpus">001004</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001004</idno><idno type="wicri:Area/Main/Curation">001004</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001004</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.</title><author><name sortKey="Putman, Michael" sort="Putman, Michael" uniqKey="Putman M" first="Michael" last="Putman">Michael Putman</name><affiliation wicri:level="1"><nlm:affiliation>Northwestern Medicine, Chicago, Illinois, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Northwestern Medicine, Chicago, Illinois</wicri:regionArea></affiliation></author><author><name sortKey="Chock, Yu Pei Eugenia" sort="Chock, Yu Pei Eugenia" uniqKey="Chock Y" first="Yu Pei Eugenia" last="Chock">Yu Pei Eugenia Chock</name><affiliation wicri:level="1"><nlm:affiliation>Yale School of Medicine, New Haven, Connecticut, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Yale School of Medicine, New Haven, Connecticut</wicri:regionArea></affiliation></author><author><name sortKey="Tam, Herman" sort="Tam, Herman" uniqKey="Tam H" first="Herman" last="Tam">Herman Tam</name><affiliation wicri:level="1"><nlm:affiliation>The Hospital for Sick Children, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Hospital for Sick Children, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Alfred H J" sort="Kim, Alfred H J" uniqKey="Kim A" first="Alfred H J" last="Kim">Alfred H J. Kim</name><affiliation wicri:level="1"><nlm:affiliation>Washington University School of Medicine, Saint Louis, Missouri, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea></affiliation></author><author><name sortKey="Sattui, Sebastian E" sort="Sattui, Sebastian E" uniqKey="Sattui S" first="Sebastian E" last="Sattui">Sebastian E. Sattui</name><affiliation wicri:level="1"><nlm:affiliation>Hospital for Special Surgery, New York, New York, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hospital for Special Surgery, New York, New York</wicri:regionArea></affiliation></author><author><name sortKey="Berenbaum, Francis" sort="Berenbaum, Francis" uniqKey="Berenbaum F" first="Francis" last="Berenbaum">Francis Berenbaum</name><affiliation wicri:level="1"><nlm:affiliation>Sorbonne Université, INSERM CRSA, AP-HP Hôpital Saint Antoine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sorbonne Université, INSERM CRSA, AP-HP Hôpital Saint Antoine, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Danila, Maria I" sort="Danila, Maria I" uniqKey="Danila M" first="Maria I" last="Danila">Maria I. Danila</name><affiliation><nlm:affiliation>University of Alabama at Birmingham.</nlm:affiliation><wicri:noCountry code="no comma">University of Alabama at Birmingham.</wicri:noCountry><wicri:noCountry code="no comma">University of Alabama at Birmingham.</wicri:noCountry></affiliation></author><author><name sortKey="Korsten, Peter" sort="Korsten, Peter" uniqKey="Korsten P" first="Peter" last="Korsten">Peter Korsten</name><affiliation wicri:level="1"><nlm:affiliation>University Medical Center Göttingen, Göttingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Medical Center Göttingen, Göttingen</wicri:regionArea></affiliation></author><author><name sortKey="Sanchez Alvarez, Catalina" sort="Sanchez Alvarez, Catalina" uniqKey="Sanchez Alvarez C" first="Catalina" last="Sanchez-Alvarez">Catalina Sanchez-Alvarez</name><affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic, Rochester, Minnesota, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Rochester, Minnesota</wicri:regionArea></affiliation></author><author><name sortKey="Sparks, Jeffrey A" sort="Sparks, Jeffrey A" uniqKey="Sparks J" first="Jeffrey A" last="Sparks">Jeffrey A. Sparks</name><affiliation wicri:level="1"><nlm:affiliation>Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts</wicri:regionArea></affiliation></author><author><name sortKey="Coates, Laura C" sort="Coates, Laura C" uniqKey="Coates L" first="Laura C" last="Coates">Laura C. Coates</name><affiliation wicri:level="1"><nlm:affiliation>University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Oxford, Oxford</wicri:regionArea></affiliation></author><author><name sortKey="Palmerlee, Candace" sort="Palmerlee, Candace" uniqKey="Palmerlee C" first="Candace" last="Palmerlee">Candace Palmerlee</name><affiliation wicri:level="1"><nlm:affiliation>••, Berkeley, California, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>••, Berkeley, California</wicri:regionArea></affiliation></author><author><name sortKey="Peirce, Andrea" sort="Peirce, Andrea" uniqKey="Peirce A" first="Andrea" last="Peirce">Andrea Peirce</name><affiliation wicri:level="1"><nlm:affiliation>••, New York, New York, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>••, New York, New York</wicri:regionArea></affiliation></author><author><name sortKey="Jayatilleke, Arundathi" sort="Jayatilleke, Arundathi" uniqKey="Jayatilleke A" first="Arundathi" last="Jayatilleke">Arundathi Jayatilleke</name><affiliation wicri:level="1"><nlm:affiliation>Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania</wicri:regionArea></affiliation></author><author><name sortKey="Johnson, Sindhu R" sort="Johnson, Sindhu R" uniqKey="Johnson S" first="Sindhu R" last="Johnson">Sindhu R. Johnson</name><affiliation wicri:level="1"><nlm:affiliation>Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Kilian, Adam" sort="Kilian, Adam" uniqKey="Kilian A" first="Adam" last="Kilian">Adam Kilian</name><affiliation wicri:level="1"><nlm:affiliation>George Washington University School of Medicine and Health Sciences, Washington, DC, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>George Washington University School of Medicine and Health Sciences, Washington, DC</wicri:regionArea></affiliation></author><author><name sortKey="Liew, Jean" sort="Liew, Jean" uniqKey="Liew J" first="Jean" last="Liew">Jean Liew</name><affiliation wicri:level="4"><nlm:affiliation>University of Washington, Seattle.</nlm:affiliation><orgName type="university">Université de Washington</orgName><country>États-Unis</country><placeName><settlement type="city">Seattle</settlement><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Prokop, Larry J" sort="Prokop, Larry J" uniqKey="Prokop L" first="Larry J" last="Prokop">Larry J. Prokop</name><affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic, Rochester, Minnesota, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Rochester, Minnesota</wicri:regionArea></affiliation></author><author><name sortKey="Murad, M Hassan" sort="Murad, M Hassan" uniqKey="Murad M" first="M Hassan" last="Murad">M Hassan Murad</name><affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic, Rochester, Minnesota, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Rochester, Minnesota</wicri:regionArea></affiliation></author><author><name sortKey="Grainger, Rebecca" sort="Grainger, Rebecca" uniqKey="Grainger R" first="Rebecca" last="Grainger">Rebecca Grainger</name><affiliation wicri:level="1"><nlm:affiliation>University of Otago, Wellington, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>University of Otago, Wellington</wicri:regionArea></affiliation></author><author><name sortKey="Wallace, Zachary S" sort="Wallace, Zachary S" uniqKey="Wallace Z" first="Zachary S" last="Wallace">Zachary S. Wallace</name><affiliation wicri:level="1"><nlm:affiliation>Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts</wicri:regionArea></affiliation></author><author><name sortKey="Duarte Garcia, Ali" sort="Duarte Garcia, Ali" uniqKey="Duarte Garcia A" first="Alí" last="Duarte-García">Alí Duarte-García</name><affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic, Rochester, Minnesota, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Rochester, Minnesota</wicri:regionArea></affiliation></author></analytic><series><title level="j">Arthritis & rheumatology (Hoboken, N.J.)</title><idno type="eISSN">2326-5205</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Azetidines (therapeutic use)</term><term>Bias (MeSH)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (mortality)</term><term>COVID-19 (physiopathology)</term><term>Chloroquine (therapeutic use)</term><term>Disease Progression (MeSH)</term><term>Glucocorticoids (therapeutic use)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunoglobulins, Intravenous (therapeutic use)</term><term>Immunologic Factors (therapeutic use)</term><term>Interleukin 1 Receptor Antagonist Protein (therapeutic use)</term><term>Janus Kinase Inhibitors (therapeutic use)</term><term>Proportional Hazards Models (MeSH)</term><term>Purines (therapeutic use)</term><term>Pyrazoles (therapeutic use)</term><term>SARS-CoV-2 (MeSH)</term><term>Sulfonamides (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antagoniste du récepteur à l'interleukine-1 (usage thérapeutique)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Azétidines (usage thérapeutique)</term><term>Biais (épidémiologie) (MeSH)</term><term>Chloroquine (usage thérapeutique)</term><term>Facteurs immunologiques (usage thérapeutique)</term><term>Glucocorticoïdes (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Immunoglobulines par voie veineuse (usage thérapeutique)</term><term>Inhibiteurs des Janus kinases (usage thérapeutique)</term><term>Modèles des risques proportionnels (MeSH)</term><term>Purines (usage thérapeutique)</term><term>Pyrazoles (usage thérapeutique)</term><term>Sulfonamides (usage thérapeutique)</term><term>Évolution de la maladie (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Azetidines</term><term>Chloroquine</term><term>Glucocorticoids</term><term>Hydroxychloroquine</term><term>Immunoglobulins, Intravenous</term><term>Immunologic Factors</term><term>Interleukin 1 Receptor Antagonist Protein</term><term>Janus Kinase Inhibitors</term><term>Purines</term><term>Pyrazoles</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagoniste du récepteur à l'interleukine-1</term><term>Anticorps monoclonaux</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Azétidines</term><term>Chloroquine</term><term>Facteurs immunologiques</term><term>Glucocorticoïdes</term><term>Hydroxychloroquine</term><term>Immunoglobulines par voie veineuse</term><term>Inhibiteurs des Janus kinases</term><term>Purines</term><term>Pyrazoles</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Bias</term><term>Disease Progression</term><term>Humans</term><term>Proportional Hazards Models</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Biais (épidémiologie)</term><term>Humains</term><term>Modèles des risques proportionnels</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID-19) and its complications. We conducted a systematic review and meta-analysis to describe the current evidence.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>A search of published and preprint databases in all languages was performed. Included studies described ≥1 relevant clinical outcome for ≥5 patients who were infected with severe acute respiratory syndrome coronavirus 2 and were treated with antirheumatic disease therapy between January 1, 2019 and May 29, 2020. Pairs of reviewers screened articles, extracted data, and assessed risk of bias. A meta-analysis of effect sizes using random-effects models was performed when possible.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The search identified 3,935 articles, of which 45 were included (4 randomized controlled trials, 29 cohort studies, and 12 case series). All studies evaluated hospitalized patients, and 29 of the 45 studies had been published in a peer-reviewed journal. In a meta-analysis of 3 cohort studies with a low risk of bias, hydroxychloroquine use was not significantly associated with mortality (pooled hazard ratio [HR] 1.41 [95% confidence interval (95% CI) 0.83, 2.42]). In a meta-analysis of 2 cohort studies with some concerns/higher risk of bias, anakinra use was associated with lower mortality (pooled HR 0.25 [95% CI 0.12, 0.52]). Evidence was inconclusive with regard to other antirheumatic disease therapies, and the majority of other studies had a high risk of bias.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>In this systematic review and meta-analysis, hydroxychloroquine use was not associated with benefit or harm regarding COVID-19 mortality. The evidence supporting the effect of other antirheumatic disease therapies in COVID-19 is currently inconclusive.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32741139</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2326-5205</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>01</Month></PubDate></JournalIssue><Title>Arthritis & rheumatology (Hoboken, N.J.)</Title><ISOAbbreviation>Arthritis Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><MedlinePgn>36-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/art.41469</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID-19) and its complications. We conducted a systematic review and meta-analysis to describe the current evidence.</AbstractText><AbstractText Label="METHODS">A search of published and preprint databases in all languages was performed. Included studies described ≥1 relevant clinical outcome for ≥5 patients who were infected with severe acute respiratory syndrome coronavirus 2 and were treated with antirheumatic disease therapy between January 1, 2019 and May 29, 2020. Pairs of reviewers screened articles, extracted data, and assessed risk of bias. A meta-analysis of effect sizes using random-effects models was performed when possible.</AbstractText><AbstractText Label="RESULTS">The search identified 3,935 articles, of which 45 were included (4 randomized controlled trials, 29 cohort studies, and 12 case series). All studies evaluated hospitalized patients, and 29 of the 45 studies had been published in a peer-reviewed journal. In a meta-analysis of 3 cohort studies with a low risk of bias, hydroxychloroquine use was not significantly associated with mortality (pooled hazard ratio [HR] 1.41 [95% confidence interval (95% CI) 0.83, 2.42]). In a meta-analysis of 2 cohort studies with some concerns/higher risk of bias, anakinra use was associated with lower mortality (pooled HR 0.25 [95% CI 0.12, 0.52]). Evidence was inconclusive with regard to other antirheumatic disease therapies, and the majority of other studies had a high risk of bias.</AbstractText><AbstractText Label="CONCLUSION">In this systematic review and meta-analysis, hydroxychloroquine use was not associated with benefit or harm regarding COVID-19 mortality. The evidence supporting the effect of other antirheumatic disease therapies in COVID-19 is currently inconclusive.</AbstractText><CopyrightInformation>© 2020, American College of Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Putman</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9699-4000</Identifier><AffiliationInfo><Affiliation>Northwestern Medicine, Chicago, Illinois, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chock</LastName><ForeName>Yu Pei Eugenia</ForeName><Initials>YPE</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, Connecticut, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam</LastName><ForeName>Herman</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5805-0639</Identifier><AffiliationInfo><Affiliation>The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Alfred H J</ForeName><Initials>AHJ</Initials><Identifier Source="ORCID">0000-0003-4074-0516</Identifier><AffiliationInfo><Affiliation>Washington University School of Medicine, Saint Louis, Missouri, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sattui</LastName><ForeName>Sebastian E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0002-3945-6828</Identifier><AffiliationInfo><Affiliation>Hospital for Special Surgery, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berenbaum</LastName><ForeName>Francis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sorbonne Université, INSERM CRSA, AP-HP Hôpital Saint Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danila</LastName><ForeName>Maria I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korsten</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6065-5680</Identifier><AffiliationInfo><Affiliation>University Medical Center Göttingen, Göttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Alvarez</LastName><ForeName>Catalina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6287-2213</Identifier><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, Minnesota, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sparks</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-5556-4618</Identifier><AffiliationInfo><Affiliation>Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coates</LastName><ForeName>Laura C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0002-4756-663X</Identifier><AffiliationInfo><Affiliation>University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmerlee</LastName><ForeName>Candace</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>••, Berkeley, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peirce</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>••, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jayatilleke</LastName><ForeName>Arundathi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sindhu R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilian</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>George Washington University School of Medicine and Health Sciences, Washington, DC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liew</LastName><ForeName>Jean</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8104-2450</Identifier><AffiliationInfo><Affiliation>University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prokop</LastName><ForeName>Larry J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, Minnesota, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murad</LastName><ForeName>M Hassan</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, Minnesota, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grainger</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9201-8678</Identifier><AffiliationInfo><Affiliation>University of Otago, Wellington, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Zachary S</ForeName><Initials>ZS</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-García</LastName><ForeName>Alí</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1749-5719</Identifier><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, Minnesota, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID-19 Global Rheumatology Alliance</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AR072577</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR070253</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AR069688</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AR075886</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR072579</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AR066953</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arthritis Rheumatol</MedlineTA><NlmUniqueID>101623795</NlmUniqueID><ISSNLinking>2326-5191</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001384">Azetidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053590">Interleukin 1 Receptor Antagonist Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075242">Janus Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>ISP4442I3Y</RegistryNumber><NameOfSubstance UI="C000596027">baricitinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>T4H8FMA7IM</RegistryNumber><NameOfSubstance UI="C504234">siltuximab</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001384" MajorTopicYN="N">Azetidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053590" MajorTopicYN="N">Interleukin 1 Receptor Antagonist Protein</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000075242" MajorTopicYN="N">Janus Kinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32741139</ArticleId><ArticleId IdType="doi">10.1002/art.41469</ArticleId><ArticleId IdType="pmc">PMC7435536</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Kim AH, Sparks JA, Liew JW, Putman MS, Berenbaum F, Duarte-García A, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19 [editorial]. Ann Intern Med 2020;172:819-21.</Citation></Reference><Reference><Citation>Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro [letter]. Cell Discov 2020;6:16.</Citation></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949.</Citation></Reference><Reference><Citation>Graef ER, Liew JW, Putman MS, Simard JF, Sirotich E, Berenbaum F, et al. Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist. Ann Rheum Dis 2020;79:734-6.</Citation></Reference><Reference><Citation>Mendel A, Bernatsky S, Thorne JC, Lacaille D, Johnson SR, Vinet É. Hydroxychloroquine shortages during the COVID-19 pandemic. Ann Rheum Dis 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis [article retracted in Lancet 2020;395:1820]. Lancet 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Mehra MR, Ruschitzka F, Patel AN. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020;395:1820.</Citation></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression [letter]. Lancet 2020;395:1033-4.</Citation></Reference><Reference><Citation>Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020;368:473-4.</Citation></Reference><Reference><Citation>Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet 2020;395:1407-9.</Citation></Reference><Reference><Citation>Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease [letter]. Lancet 2020;395:e30-1.</Citation></Reference><Reference><Citation>Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity, inflammation and intervention [review]. Nat Rev Immunol 2020;20:363-74.</Citation></Reference><Reference><Citation>Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). Int J Rheum Dis 2020;23:613-9.</Citation></Reference><Reference><Citation>Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al, editors. Cochrane handbook for systematic reviews of interventions: version 6.0, 2019. July 2019. URL: www.training.cochrane.org/handbook.</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12.</Citation></Reference><Reference><Citation>Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ 2020;368:l6890.</Citation></Reference><Reference><Citation>NIHR. PROSPERO international prospective register of systematic reviews. Preclinical and clinical outcomes of rheumatic disease therapy in patients with COVID-19 infection: a systematic review. April 2020. URL: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=176896.</Citation></Reference><Reference><Citation>Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.</Citation></Reference><Reference><Citation>Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.</Citation></Reference><Reference><Citation>Viswanathan M, Patnode CD, Berkman ND, Bass EB, Chang S, Hartling L, et al. Recommendations for assessing the risk of bias in systematic reviews of health-care interventions. J Clin Epidemiol 2018;97:26-34.</Citation></Reference><Reference><Citation>Dekkers OM, Egger M, Altman DG, Vandenbroucke JP. Distinguishing case series from cohort studies. Ann Intern Med 2012;156:37-40.</Citation></Reference><Reference><Citation>Mathes T, Pieper D. Clarifying the distinction between case series and cohort studies in systematic reviews of comparative studies: potential impact on body of evidence and workload. BMC Med Res Methodol 2017;17:107.</Citation></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.</Citation></Reference><Reference><Citation>McKenzie JE, Brennan S. Synthesizing and presenting findings using other methods. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editors. Cochrane handbook for systematic reviews of interventions version 6.0 2019. URL: https://training.cochrane.org/handbook/current/chapter-12.</Citation></Reference><Reference><Citation>Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020;323:2493-502.</Citation></Reference><Reference><Citation>Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. medRxiv 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Mahévas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:m1844.</Citation></Reference><Reference><Citation>Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 2020;382:2411-8.</Citation></Reference><Reference><Citation>Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020;369:m1849.</Citation></Reference><Reference><Citation>Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Mallat J, Hamed F, Balkis M, Mohamed MA, Mooty M, Malik A, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: a retrospective study. medRxiv 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 2020;3:e208857.</Citation></Reference><Reference><Citation>Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. Treating COVID-19 with chloroquine. J Mol Cell Biol 2020;12:322-5.</Citation></Reference><Reference><Citation>Huang M, Li M, Xiao F, Pang P, Liang J, Tang T, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19 [review]. Nat Sci Rev 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Chen X, Zhang Y, Zhu B, Zeng J, Hong W, He X, et al. Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study. April 2020. URL: http://medrxiv.org/lookup/doi/10.1101/2020.04.09.20058941.</Citation></Reference><Reference><Citation>Roumier M, Paule R, Groh M, Vallee A, Ackermann F. Interleukin-6 blockade for severe COVID-19. April 2020. URL: http://medrxiv.org/lookup/doi/10.1101/2020.04.20.20061861.</Citation></Reference><Reference><Citation>Klopfenstein T, Zayet S, Lohse A, Balblanc JC, Badie J, Royer PY, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mals Infect 2020;50:397-400.</Citation></Reference><Reference><Citation>Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M, Pecori D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care. J Clin Virol 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Wang D, Wang J, Jiang Q, Yang J, Li J, Gao C, et al. No clear benefit to the use of corticosteroid as treatment in adult patients with coronavirus disease 2019: a retrospective cohort study. April 2020. URL: http://medrxiv.org/lookup/doi/10.1101/2020.04.21.20066258.</Citation></Reference><Reference><Citation>Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia [letter]. Sig Transduct Target Ther 2020;5:57.</Citation></Reference><Reference><Citation>Fadel R, Morrison A, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, et al. Early short course corticosteroids in hospitalized patients with COVID-19. May 2020. URL: https://www.medrxiv.org/content/10.1101/2020.05.04.20074609v1.</Citation></Reference><Reference><Citation>Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl) 2020;133:1039-43.</Citation></Reference><Reference><Citation>Chen X, Ling J, Mo P, Zhang Y, Jiang Q, Ma Z, et al. Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients. March 2020. URL: http://medrxiv.org/lookup/doi/10.1101/2020.03.03.20030437.</Citation></Reference><Reference><Citation>Fang X, Mei Q, Yang T, Li L, Wang Y, Tong F, et al. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19 [letter]. J Infect 2020;81:147-78.</Citation></Reference><Reference><Citation>Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Cavalli G, de Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020;2:e325-31.</Citation></Reference><Reference><Citation>Shao Z, Feng Y, Zhong L, Xie Q, Lei M, Liu Z, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: a multicenter retrospective cohort study. April 2020. URL: medRxiv 2020:2020.04.11.20061739.</Citation></Reference><Reference><Citation>Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. February 2020. URL: http://medrxiv.org/lookup/doi/10.1101/2020.02.17.20024166.</Citation></Reference><Reference><Citation>Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X, et al. Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 2020;71:748-55.</Citation></Reference><Reference><Citation>Qi X, Liu Y, Wang J, Fallowfield JA, Wang J, Li X, et al. Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study. Gut 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact [letter]. J Infect 2020;81:318-56.</Citation></Reference><Reference><Citation>Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology guidance for the management of rheumatic diseases in adult patients during the COVID-19 pandemic: version 1. Arthritis Rheumatol 2020;72:1241-51.</Citation></Reference><Reference><Citation>Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>RECOVERY. Randomised evaluation of COVID-19 therapy. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. June 2020. URL: https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19.</Citation></Reference><Reference><Citation>World Health Organization. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. July 2020. URL: https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19.</Citation></Reference><Reference><Citation>National Institutes of Health. News releases. NIH halts clinical trial of hydroxychloroquine. June 2020. URL: https://www.nih.gov/news-events/news-releases/nih-halts-clinical-trial-hydroxychloroquine.</Citation></Reference><Reference><Citation>Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>RECOVERY. Randomised evaluation of COVID-19 therapy. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. June 2020. URL: https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19.</Citation></Reference><Reference><Citation>Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al, for the RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19: preliminary report. N Engl J Med 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med 2020;48:e440-69.</Citation></Reference><Reference><Citation>Poston JT, Patel BK, Davis AM. Management of critically ill adults with COVID-19. JAMA 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 2020;24:4040-7.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. National Library of Medicine. Eculizumab (Soliris) in COVID-19 infected patients (SOLID-C19). March 2020. URL: https://clinicaltrials.gov/ct2/show/NCT04288713.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. National Library of Medicine. Octagam 10% therapy in COVID-19 patients with severe disease progression. August 2020. URL: https://clinicaltrials.gov/ct2/show/NCT04400058.</Citation></Reference><Reference><Citation>Yu B, Wang DW, Li C. Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. May 2020. URL: http://medrxiv.org/lookup/doi/10.1101/2020.04.27.20073379.</Citation></Reference><Reference><Citation>Ashraf MA, Shokouhi N, Memar O, Sanginabadi M, Ghaderkhani S. COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes. April 2020. URL: https://www.medrxiv.org/content/10.1101/2020.04.20.20072421v1.</Citation></Reference><Reference><Citation>Mathian A, Mahévas M, Rohmer J, Roumier M, Cohen-Aubert F, Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine [letter]. Ann Rheum Dis 2020;79:837-9.</Citation></Reference><Reference><Citation>Molina JM, Delaugerre C, le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection [letter]. Med Mal Infect 2020;50:384.</Citation></Reference><Reference><Citation>Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 2020:101738.</Citation></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis 2020;34:101663.</Citation></Reference><Reference><Citation>Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol 2020;38:529-32.</Citation></Reference><Reference><Citation>Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020;92:814-8.</Citation></Reference><Reference><Citation>Alattar R, Ibrahim TB, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Gritti G, Raimondi F, Ripamonti D, Riva I, Landi F, Alborghetti L, et al. Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. June 2020. URL: http://medrxiv.org/lookup/doi/10.1101/2020.04.01.20048561.</Citation></Reference><Reference><Citation>Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020;117:10970-5.</Citation></Reference><Reference><Citation>Lu X, Chen T, Wang Y, Wang J, Yan F. Adjuvant corticosteroid therapy for critically ill patients with COVID-19 [letter]. Crit Care 2020;24:241.</Citation></Reference><Reference><Citation>Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020. E-pub ahead of print.</Citation></Reference><Reference><Citation>Shi Q, Zhao K, Yu J, Jiang F, Feng J, Zhao K, et al. Clinical characteristics of 101 COVID-19 nonsurvivors in Wuhan, China: a retrospective study. May 2020. URL: http://medrxiv.org/lookup/doi/10.1101/2020.03.04.20031039.</Citation></Reference><Reference><Citation>Jacobs JP, Stammers AH, St. Louis J, Hayanga JW, Firstenberg MS, Mongero LB, et al. Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in COVID-19: experience with 32 patients. ASAIO J 2020;66:722-30.</Citation></Reference><Reference><Citation>Chen M, Tu C, Tan C, Zheng X, Wang X, Wu J, et al. Key to successful treatment of COVID-19: accurate identification of severe risks and early intervention of disease progression. April 2020. URL: http://medrxiv.org/lookup/doi/10.1101/2020.04.06.20054890.</Citation></Reference><Reference><Citation>Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis 2020. E-pub ahead of print.</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001004 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001004 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:32741139
|texte= Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:32741139" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |